| Literature DB >> 31965606 |
Jeremy A O'Sullivan1, Alan T Chang2, Bradford A Youngblood2, Bruce S Bochner1.
Abstract
Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit. ©2020 Society for Leukocyte Biology.Entities:
Keywords: AK002; Siglec; antolimab; eosinophils; ligands; mast cells; signaling
Mesh:
Substances:
Year: 2020 PMID: 31965606 PMCID: PMC7531194 DOI: 10.1002/JLB.2MR0120-352RR
Source DB: PubMed Journal: J Leukoc Biol ISSN: 0741-5400 Impact factor: 4.962